ROS1-dependent cancers—biology, diagnostics and therapeutics
A Drilon, C Jenkins, S Iyer, A Schoenfeld… - Nature reviews Clinical …, 2021 - nature.com
The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …
Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation
C Heydt, CB Wölwer, O Velazquez Camacho… - BMC medical …, 2021 - Springer
Background Gene fusions represent promising targets for cancer therapy in lung cancer.
Reliable detection of multiple gene fusions is therefore essential. Methods Five …
Reliable detection of multiple gene fusions is therefore essential. Methods Five …
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort …
A Kästner, A Kron, N van den Berg, K Moon… - The Lancet Regional …, 2024 - thelancet.com
Summary Background The national Network Genomic Medicine (nNGM) Lung Cancer
provides comprehensive and high-quality multiplex molecular diagnostics and standardized …
provides comprehensive and high-quality multiplex molecular diagnostics and standardized …
Sequencing strategies for fusion gene detection
EE Heyer, J Blackburn - Bioessays, 2020 - Wiley Online Library
Fusion genes formed by chromosomal rearrangements are common drivers of cancer.
Recent innovations in the field of next‐generation sequencing (NGS) have seen a dynamic …
Recent innovations in the field of next‐generation sequencing (NGS) have seen a dynamic …
Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays
N Pfarr, M Kirchner, U Lehmann… - Genes …, 2020 - Wiley Online Library
NTRK fusions involving three neurotrophic tyrosine receptor kinase genes NTRK1, NTRK2,
and NTRK3 and a variety of fusion partners were identified as oncogenic drivers across …
and NTRK3 and a variety of fusion partners were identified as oncogenic drivers across …
Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer
CC Cheung, AC Smith, R Albadine, G Bigras… - Lung Cancer, 2021 - Elsevier
Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1)
gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) …
gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) …
[HTML][HTML] Evaluating targeted next-generation sequencing assays and reference materials for NTRK fusion detection
CB Chung, J Lee, M Barritault, PP Bringuier… - The Journal of Molecular …, 2022 - Elsevier
Neurotrophic tyrosine receptor kinase (NTRK1/2/3) fusions are oncogenic drivers in
approximately 0.3% of solid tumors. High-quality testing to identify patients with NTRK fusion …
approximately 0.3% of solid tumors. High-quality testing to identify patients with NTRK fusion …
ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals
NJ Myall, M Das - Current Problems in Cancer, 2024 - Elsevier
Rearrangements involving the ROS1 gene are infrequent in non-small cell lung cancer
(NSCLC) but represent an important targetable driver alteration. Occurring most commonly …
(NSCLC) but represent an important targetable driver alteration. Occurring most commonly …
[HTML][HTML] High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
Y Xu, H Chang, L Wu, X Zhang, L Zhang… - … and molecular pathology, 2020 - Elsevier
ROS1 rearrangement has become an important biomarker for targeted therapy in advanced
lung adenocarcinoma (LUAD). The study aimed to evaluate the prevalence of ROS1 …
lung adenocarcinoma (LUAD). The study aimed to evaluate the prevalence of ROS1 …
Diagnosis of NUT carcinoma despite false-negative next-generation sequencing results: a case report and literature review
X Wang, J Wang, X Luo, J Lu, L Wang, Q Li… - OncoTargets and …, 2021 - Taylor & Francis
Nuclear protein in testis (NUT) carcinoma (NC) is a poorly differentiated malignant tumor
with a poor prognosis, which is caused by the NUTM1 gene rearrangement. Positive …
with a poor prognosis, which is caused by the NUTM1 gene rearrangement. Positive …